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Abstract Current adherence assessments typically detect
missed doses long after they occur. Real-time, wireless
monitoring strategies for antiretroviral therapy may provide
novelopportunitiestoproactivelypreventvirologicrebound
and treatment failure. Wisepill, a wireless pill container that
transmits a cellular signal when opened, was pilot tested in
ten Ugandan individuals for 6 months. Adherence levels
measured by Wisepill, unannounced pill counts, and self-
report were compared with each other, prior standard elec-
tronicmonitoring,andHIVRNA.Wisepilldatawasinitially
limited by battery life and signal transmission interruptions.
Following device improvements, continuous data was
achieved with median (interquartile range) adherence levels
of 93% (87–97%) by Wisepill, 100% (99–100%) by unan-
nounced pill count, 100% (100–100%) by self-report, and
92%(79–98%)bypriorstandardelectronicmonitoring.Four
individuals developed transient, low-level viremia. After
overcoming technical challenges, real-time adherence
monitoring is feasible for resource-limited settings and may
detect suboptimal adherence prior to viral rebound.
Keywords Real-time adherence monitoring 
Wireless technology  Antiretroviral therapy
Introduction
Current approaches to antiretroviral therapy (ART) adher-
ence monitoring include various forms of structured patient
interview (also known as self-report), pill counts, pharmacy
reﬁll, and electronic monitoring [1]. In practice, all of these
methods are assessed on an intermittent basis, such that
missed doses are detected several weeks to months after
they occur. They are therefore often unable to direct
adherence interventions before resumption of viral repli-
cation, which can lead to treatment failure and drug resis-
tance. Loss of viral suppression may begin as early as 48 h
after a lapse in adherence, and a 15-day interruption confers
a 50% chance of virologic failure among suppressed indi-
viduals on non-nucleoside reverse transcriptase inhibitor
therapy [2]. Real-time adherence monitoring could allow
for the detection of adherence lapses and interventions to
resume treatment prior to the development of virologic
rebound and drug resistance, which has not previously been
possible [3]. This real-time approach is particularly
important in settings with limited treatment options in that
resources for behavioral and structural interventions could
be directed speciﬁcally at identiﬁed adherence lapses.
The Wisepill adherence monitor (see Fig. 1; Wisepill
Technologies, Cape Town, South Africa) communicates
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DOI 10.1007/s10461-010-9799-4dosing behavior in real-time by transmission of a patient
identiﬁer and date-time stamp over existing cellular net-
works when the container is opened to take medications.
Similar real-time monitoring devices are being pilot tested
for various healthcare uses, such as infection control and
oral hygiene, in developed settings [4, 5]. Because cellular
network coverage is becoming ubiquitous globally [6],
including large segments of Africa, the technical infra-
structure now exists for real-time adherence monitoring in
resource-limited settings. While excitement abounds for
wireless technologies to support healthcare delivery,
especially in developing settings, few studies have pro-
vided evidence of feasibility, acceptability, and perfor-
mance [7].
This study presents proof-of-concept data from the ﬁrst
6 months of wireless ART adherence monitoring among
ten patients in rural Uganda.
Methods
Study Site
ThispilotstudytookplaceinMbarara,Uganda,whichisarural
area located in southwestern part of the country near the bor-
ders with Rwanda andthe Democratic Republic of the Congo.
Study Population
The ten participants were recruited from the Ugandan ART
Rural Treatment Outcomes (UARTO) Study, an existing
prospective structured interval cohort of 500 adults fol-
lowed for ART adherence at the Mbarara University of
Science and Technology (MUST). Participants had prior
adherence monitoring with monthly visual analog scale
(VAS) for doses taken over the previous 30 days, self-
reported recall of doses missed over the previous 3 days,
and unannounced home-based pill count, as well as elec-
tronic monitoring with the medication event monitoring
system (MEMS) for at least 1 year. Adequate cellular
signal (at least three of ﬁve bars) was conﬁrmed at all
participants’ homes prior to enrollment in the study.
Wireless Adherence Monitoring Device and System
Speciﬁcations
Wisepill holds approximately 30 large pills or 60 small
pills in a two-compartment inner container and is powered
by a 1,100 mA lithium polymer rechargeable battery
(Great Power Battery Ltd, Hong Kong). Every time the
device is opened, a cellular signal is sent and recorded in
real-time on a web-based server, which is housed in Cape
Town, South Africa. The data is then immediately acces-
sible to research staff via a secure Internet interface. Power
failure is mitigated with a signaling subsystem in which
non-volatile EEprom (ﬂash memory) maintains data for
later transmission if connectivity is lost. Each Wisepill
device contains a SIM card, and data are transmitted
primarily by general packet radio service (GPRS) to a
web-based server. Data transfer may also occur via short
message service (SMS); however, GPRS is preferred
becauseit isless expensive and, unlike SMS, doesnotdelete
data until receipt is conﬁrmed by the server. A forwarder
(Wisepill Technologies) is required to transfer the SMS
signal to the server and is located physically in Mbarara,
Uganda. In addition to recording device openings, the
Wisepill signal reports the remaining battery power for the
device, airtime on the SIM card, and strength of the signal.
Improvements were made to the Wisepill devices in
between the two 3-month study periods. Speciﬁcally, the
hardware for the forwarder was upgraded and monitoring
of the forwarder function was enabled through the server.
The Wisepill battery life was also expanded from approx-
imately 6 weeks to 4 months (assuming two device open-
ings per day) by maximizing the efﬁciency of sleep modes
in between events.
Signal Lapses
Lapses in Wisepill signals lasting greater than 48 h were
investigated by phone and/or home visit to determine if the
cause was a technical failure, behavioral, or unclear.
Technical failure was classiﬁed as low battery power, low
airtime on the device SIM card, forwarder malfunction,
Fig. 1 The Wisepill device
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123device malfunction, or other. Behavioral causes were
classiﬁed based on patient interview as missed doses (e.g.
forgetting, lack of drug supply), intentional non-use (e.g.
storage of pills in an alternate container), or other. The
cause of the interruption was classiﬁed as unclear if no
technical failure could be identiﬁed and the participant
reported opening the device to take pills.
Adherence Measures
Adherence data was collected for all participants over two
3-month periods between March and December 2009. We
calculated an adjusted Wisepill adherence to account for
technical failures of the device or loss of signal. The time
period during the technical lapse was censored, whereas
lapses in the absence of a clear technical failure were
classiﬁed as missed doses. Adherence was also measured
monthly with a 30-day VAS, a 3-day self-reported recall
of missed doses, and an unannounced pill count con-
ducted in the participants’ homes. Pill count adherence
levels were truncated at 100%, as adherence over this
amount typically reﬂects lost or shared medication and
this method of adherence measurement is inherently
unable to account for such phenomena. MEMS adherence
data was available for the 3 months just prior to Wisepill
implementation in six participants. MEMS data was not
available in the other four participants due to device
malfunction or loss.
Acceptability
Acceptability of Wisepill was determined 1 month after
initiation of the pilot through the use of a quantitative
and open-ended questionnaire. Questions addressed the
participants’ opinions of using the device, including ease
or difﬁculty of use; how they store the device and use it
during travel; potential stigma and loss of conﬁdentiality
from using the device; appropriateness of this device
in a poor rural setting; and opinions of real-time
monitoring ultimately to be coupled with real-time
intervention. All questions were translated into the local
language of Runyankole and back translated to English
for accuracy.
HIV RNA Levels
HIV RNA was determined a median of 17 days (IQR
6–36) days prior to baseline and approximately every
3 months thereafter using the Roche Amplicor Assay with
a lower level of detection of 40 copies/ml [8]. HIV RNAs
were missing for two participants at the end of the study
period.
Ethical Review
This study was approved by the ethical review boards at
MUST, the Partners Human Research Committee at Mas-
sachusetts General Hospital, and the Uganda National
Council for Science and Technology.
Results
Participants
The median age for the ten participants at enrollment was
38 (interquartile range 34–46) years, eight were female,
four were employed away from home, two lived more than
20 km from the clinic, nine took ART twice daily, and one
took ART once daily. Eight participants took a three-drug
ﬁxed dose combination pill (seven took zidovudine/lami-
vudine/ nevirapine; one took stavudine/lamivudine/nevir-
apine). The remaining two took a two-drug ﬁxed dose
combination pill (zidovudine/lamivudine) plus efavirenz,
storing one pill in the Wisepill and the other pill in a
standard medication bottle. The mean time on ART was
19.2 months at enrollment into the pilot. All participants
had undetectable HIV RNA less than 40 copies/ml at
enrollment, except one who had 60 copies/ml.
Wisepill Data Transmission and Adherence Lapses
Approximately 90% of Wisepill transmissions occurred via
GPRS. Adequate cellular signal was reported for all devi-
ces except one, which had intermittent gaps. During the
ﬁrst 3 months of the study, a total of 1,959 events were
expected for all ten participants. Technical problems con-
sisted of 23 battery failures and seven forwarder mal-
functions, causing a loss of 192 events (9.8%; Table 1).
Twenty of the battery failures and three of the forwarder
malfunctions resulted in lapses in the Wisepill signal of
greater than 48 h. An additional three lapses occurred for
unclear reasons. The median duration of these lapses was
3.1 days (IQR 2.3–3.6).
During the second 3 months of the study, the only
technical problem was a single battery failure after
Table 1 Technical problems detected in the ﬁrst and second three-
month periods of the study
Technical problems First
3 months
Second
3 months
Battery failures 23 1
Forwarder malfunctions 7 0
Total 30 1
Percentage of expected events 9.8 0.3
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1232.5 months of use. There were no problems with the for-
warder. Four lapses in the Wisepill signal of greater than
48 h occurred. One lapse was due to the battery failure.
Another was intentional because the participant did not
want to travel with the Wisepill device and put 1-week’s
worth of pills in his pocket. The causes of the other two
lapses are unclear. The median duration of the 48-h lapses
was 3.7 days (IQR 2.7–5.1).
One week following the conclusion of the pilot, all
devices ceased to work on the same day. Thorough
investigations revealed that the SIM cards in the Wisepill
device had expired because no airtime had been added in
the previous 90 days.
Adherence Levels
Median adherence levels by each measure are shown in
Fig. 2. Eight of 54 (14.8%) unannounced pill counts were
truncated to 100% with a maximum recorded value of
104.3%.
HIV RNA Suppression
The participant with a baseline HIV RNA of 60 copies/ml
had two subsequently measurements at 51 copies/ml and
undetectable. Three additional patients had transient viral
rebounds (58, 134, and 627 copes/ml) in the second
3-month period, which subsequently became undetectable.
Figure 3 shows the adherence dot plots in the 14 days prior
to each of these detectable HIV RNA measurements. No
Wisepill interruptions of greater than 48 h occurred,
although between ﬁve and eight missed events without a
48-h interruption were observed in three of the four
participants. When assessing the nine participants during
the ﬁrst 3-month period and the seven participants during
the second 3-month period who had undetectable HIV
RNA, one participant had one Wisepill interruption that
was attributed to a battery failure and 13 (81%) partici-
pants had between one and nine missed events without a
48-h interruption during the 14 days prior to HIV RNA
testing.
Acceptability
All participants described Wisepill as ‘‘easy or very easy’’
or ‘‘convenient or very convenient’’ to use. They all felt the
device attracted attention, but the attention did not bother
them primarily because the device did not look like a tra-
ditional pill container. Wisepill did not lead to any reported
disclosures of HIV status. When asked ‘‘How do you feel
about someone monitoring how you are taking your pills
every day?’’ all participants responded ‘‘ok’’ or ‘‘liked it’’.
One participant felt it improved adherence. Concerns about
the device included a limited pill capacity and the need to
change the battery. One participant with impaired vision
had trouble interpreting the meaning of the ﬂashing lights
during signal transmission, whereas others found the lights
reassuring. Three participants expressed concern about
traveling with Wisepill primarily because they were con-
cerned about losing or damaging such an expensive device.
Such concern resulted in one participant not using the
device for 1 week, as noted above.
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Fig. 2 Median adherence
levels by multiple measures
averaged over the two 3-month
study periods. * MEMS data
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initiation of this study
AIDS Behav (2010) 14:1340–1346 1343
123Discussion
The results of this pilot study suggest that real-time
adherence monitoring is feasible in a resource-limited
setting. The initial 3 months of data collection revealed
signiﬁcanttechnicalproblems;however,mostwereresolved
during the course of the study. Minor modiﬁcations to the
sleep mode extended the battery life to nearly 4 months for
almost all issued devices, and SMS signal transmission
becamereliablethroughupgradestotheforwarder.TheSIM
card expiration after the conclusion of this pilot study
occurred despite monitoring the level of airtime available.
Research staff were unaware that the network coverage
provider automatically inactivates the SIM cards if no air-
time is added during a 6-month period, and contract pre-
paymentplansarenotavailable.Thisﬁndingunderscoresthe
importance of in ﬁeld-testing for novel technologies.
Although the adherence levels assessed with Wisepill
were similar to those made with prior electronic monitoring
through MEMS, they were lower than the adherence levels
determined by unannounced pill counts and self-report. It is
not known which measure is correct, as there is no gold
standard for adherence measurement. Moreover, the sam-
ple size in this pilot study is too small to determine the
statistical signiﬁcance of any differences among the mea-
surements. The apparent discrepancy between unan-
nounced pill count and electronic monitoring, both of
which are objective measures, may be due to patients
returning unused medications to the pharmacist during
reﬁlls and other inconsistencies during medication dis-
bursement. Alternatively, participants may have removed
more than one pill at a time or further technical problems
with Wisepill could have gone undetected, thus leading to
falsely low adherence measurements. Undetected technical
problems may also explain some of the difference in
Wisepill adherence in the ﬁrst and second 3-month periods.
Additionally, the adherence levels as measured by both
MEMS and Wisepill were lower than similar data from
other studies [9, 10], which may reﬂect the relatively long
duration of treatment of the participants in this study. The
decline in adherence is consistent with data showing that
highly adherent individuals may experience a modest
decline in adherence over time [9, 11].
Both 3-month time periods had similar rates of lapses in
the Wisepill signal that could not be classiﬁed as a speciﬁc
technical or behavioral cause. These unclear lapses may
reﬂect missed doses that were not reported due to social
desirability bias against disclosure of missed doses. This
type of bias is common and can lead to under-reporting of
incomplete adherence [12]. Interventions to address the
lapses detected through Wisepill will therefore need to
consider culturally acceptable means of determining both
the cause of missed doses and appropriate responses. It is
also possible that lapses of unclear cause could indicate
undetected technical failures, despite the ongoing checks of
signal strength, airtime, and battery power, as well as
Fig. 3 Adherence dot plots for the 14 days prior to detection of the
transient, low-level viremia seen in four participants. a HIV RNA 627
copies/ml (6/15/09; ﬁrst 3-month period); b HIV RNA 134 copies/ml
(8/11/09; second 3-month period); c HIV RNA 58 copies/ml (8/18/09;
second 3-month period); d HIV RNA 51 copies/ml (8/24/09; second
3-month period)
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123transmission of signals stored during temporary loss of the
cellular network. To further decrease the likelihood of
technical failures, the manufacturer is currently adding an
automated daily signal, which will serve as a positive
control of the device’s functionality.
Interventions targeted to individuals with known
adherence lapses have been shown to be more effective
than untargeted interventions [13, 14], and real-time
adherence monitoring could be used to direct interventions
to speciﬁc missed doses prior to virologic rebound. Such a
‘‘just-in-time’’ approach may increase effectiveness further
[15, 16]. For example, automated SMS reminders could be
triggered by missed or late doses, or a community health
worker could call or personally visit a patient during an
adherence lapse to intervene before viral rebound.
The pilot data showed that real-time adherence moni-
toring was acceptable to all participants. Many found
Wisepill desirable, easy to use, and/or thought it helped
them remember to take their doses. One limitation to these
ﬁndings is that the study population consisted of individ-
uals already accustomed to the use of MEMS caps, which
may select for acceptance of the Wisepill device as well.
The generalizability and sustainability of this initial
enthusiasm will have to be determined in larger popula-
tions over time, and these assessments will be critical for
the scalability of this technology. Several theories and
models of technology acceptance have been developed to
best understand the experience of the end user, such as the
Technology Acceptance Model and the Uniﬁed Theory of
Acceptance and Use of Technology [17–19]. These models
build upon the theory of reasoned action [20] and include
elements such as perceived usefulness, perceived ease of
use, output quality, social inﬂuence, attitude, behavioral
intention to use, and actual use. Moreover, standard elec-
tronic medication containers have known facilitators and
barriers to uptake, such as the container acting as a
reminder and incompatibility with pill boxes, respectively
[21]. While this study was too small in scope to inform a
theoretical model, future efforts to implement real-time
adherence monitoring should consider underlying theory
and previous research.
Several individuals in this study experienced transient
low-level viremia, consistent with blips [22]. While
transient low-level viremia has been associated with
transient periods of incomplete adherence [23], we were
unable to assess such an association in our small pilot
study. This study does, however, provide proof-of-con-
cept that participants can be contacted during potential
adherence lapses. In future studies, HIV RNA could be
assessed during the adherence lapse to determine how
quickly viral rebound occurs in this setting and to what
extent it can be re-suppressed without the development of
drug resistance.
Studies have shown that ART adherence predicts viral
rebound, drug resistance, and morbidity and mortality from
HIV/AIDS [24–26]. Furthermore, relatively crude phar-
macy reﬁll adherence monitoring may be a better predictor
of viral rebound than the standard practice of CD4 response
for detecting treatment failure [27]. More accurate adher-
ence monitoring, such as can be achieved through a real-
time approach, may help prioritize limited resources for
HIV RNA monitoring to those at increased risk for viral
bound.
The ﬁndings of this study reﬂect a small sample in a
research context. Future research should aim to expand the
number of participants and establish the data and manage-
ment structure necessary to test the efﬁcacy of detecting
virologic rebound in real time, and ultimately how such
real-time detection of virologic rebound can be linked to
interventions that improve patient outcomes in clinical
practice. Cost is another concern. Although the Wisepill
device currently costs US$185; mass production could
lower the price to US$20–30. Signiﬁcant cost savings could
be achieved through economies of scale, as well as targeted
use of HIV RNA monitoring and reduced need for second
line therapies. Such savings couldbringreal-time adherence
monitoring into the same cost range as CD4 monitoring.
In sum, real-time adherence monitoring deﬁnes a fea-
sible and acceptable strategy to proactively prevent rather
than reactively respond to virologic treatment failure and
thereby extend the duration of ﬁrst-line therapy. Further
studies should build on this pilot data to determine the
efﬁcacy of real-time intervention for sustained adherence
and its potential to act as a surrogate for HIV RNA testing.
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